Accessibility Statement

Accessibility statement for Yellow Card Reporting website

 

This accessibility statement applies to the domain http:// yellowcard.mhra.gov.uk.

This website is run by the Medicines and Healthcare products Regulatory Agency (MHRA). We want as many people as possible to be able to use this website. For example, that means you should be able to:

  • change colours, contrast levels and fonts
  • zoom in up to 300% without the text spilling off the screen
  • navigate most of the website using just a keyboard
  • navigate most of the website using speech recognition software
  • listen to most of the website using a screen reader (including the most recent versions of JAWS, NVDA and VoiceOver)

We’ve also made the website text as simple as possible to understand.

AbilityNet has advice on making your device easier to use if you have a disability.

 

How accessible this website is

We know some parts of this website are not fully accessible:

  • There are some elements missing proper labels or attributes
  • Alternative text is not available for all visual content
  • Not all areas of the site (drug profiles) can be accessed by those using a screen reader or keyboard
  • The site is not responsive

Feedback and contact information

If you need information on this website in a different format like accessible PDF, large print, easy read, audio recording or braille:

  • email webupdates@mhra.gov.uk

We’ll consider your request and get back to you in 18 working days.

 

Reporting accessibility problems with this website

We’re always looking to improve the accessibility of this website. If you find any problems not listed on this page or think we’re not meeting accessibility requirements, contact webupdates@mhra.gov.uk

 

Enforcement procedure

The Equality and Human Rights Commission (EHRC) is responsible for enforcing the Public Sector Bodies (Websites and Mobile Applications) (No. 2) Accessibility Regulations 2018 (the ‘accessibility regulations’). If you’re not happy with how we respond to your complaint, contact the Equality Advisory and Support Service (EASS).

 

Technical information about this website’s accessibility

The MHRA is committed to making its websitea accessible, in accordance with the Public Sector Bodies (Websites and Mobile Applications) (No. 2) Accessibility Regulations 2018.

This website is partially compliant with the Web Content Accessibility Guidelines version 2.1 AA standard, due to ‘the non-compliances’ listed below.

 

Non-accessible content

The content listed below is non-accessible for the following reasons.

Non-compliance with the accessibility regulations

The ‘Sign in or Register’ button cannot be operated with a keyboard (WCAG 2.1 success criteria 2.1.1)

No skip link is provided to bypass repeated sections of content (WCAG 2.1 success criteria 2.4.1)

After tabbing through the links in the footer, a hidden link, checkbox and button receives focus (WCAG 2.1 success criteria 2.4.3)

An obvious focus indicator is missing on interactive elements of the Cookie overlay (WCAG 2.1 success criteria 2.4.7)

A link in the banner is incorrectly marked as a heading (WCAG 2.1 success criteria 1.3.1)

Some of the links do not have proper descriptive text (WCAG 2.1 success criteria 2.4.4)

Some elements are not nested according to their specifications (WCAG 2.1 success criteria 4.1.1)

There is a colour contrast issue on the ‘About you’ page (WCAG 2.1 success criteria 1.4.3)

The browser zoom function cannot be increased above 150% before scrolling is required in more than one direction (WCAG 2.1 success criteria 1.4.10)

There is a colour contrast issue on the page for reporting a defective product (WCAG 2.1 success criteria 1.4.11)

Tooltips appear and are not dismissable when hovering over question mark icons on Interactive Drug Analysis Profiles (WCAG 2.1 success criteria 1.4.13)

Alternative text is not provided for all linked images (WCAG 2.1 success criteria 1.1.1)

No audio description or media alternative is available for videos held on some pages and captions contain incorrect words (WCAG 2.1 success criteria 1.2.3, 1.2.5 and 1.2.2)

Content that should be marked as a heading is not and a heading is set at the wrong level (WCAG 2.1 success criteria 1.3.1)

The page title is the same across all pages in the site (WCAG 2.1 success criteria 2.4.2)

Headings on the Interactive Drug Analysis Profiles are not descriptive (WCAG 2.1 success criteria 2.4.6)

No autocomplete function is available on the Contact us and Register inputs (WCAG 2.1 success criteria 1.3.5)

The language of the page is not identifiable by assistive technologies as English (WCAG 2.1 success criteria 3.1.1)

Custom elements for showing/hiding content are difficult to use with assistive technologies (WCAG 2.1 success criteria 4.1.2)

Links are not marked up to announce changes to content when navigating the A-Z function in the Interactive Drug Analysis Profiles (WCAG 2.1 success criteria 4.1.3)

No autocomplete function is available on several inputs (WCAG 2.1 success criteria 1.3.5)

Animations start automatically and loop continuously (WCAG 2.1 success criteria 2.2.2)

Error messages do not provide suggestions to the user to rectify the issue (WCAG 2.1 success criteria 3.3.3)

 

Disproportionate burden

We are currently rebuilding this service on a new system, work which is currently in a development stage and is due to be completed by mid-2021.  We will adhere to the Web Content Accessibility Guidelines version 2.1. AA standard for all new and amended content and pages as the service is built. 

We have assessed the cost of fixing the issues identified on the existing site that is scheduled to be replaced and believe that doing so now would be a disproportionate burden within the meaning of the accessibility regulations.

 

 

What we’re doing to improve accessibility

A comprehensive manual audit of the site was carried out by an expert third party in June 2020.  

We are currently rebuilding this service on a new system: it is in a development stage and we are seeking public feedback.  As we continue to develop the service we will improve accessibility.  We will adhere to the Web Content Accessibility Guidelines version 2.1. AA standard for all new and amended content and pages as the service is built. 

Test failures from the existing system have been reported to our development team to take into account with the new system build and we will conduct a comprehensive manual audit of the new site before the system goes live.  This work is expected to be completed by mid-2021.

 

Preparation of this accessibility statement

This statement was prepared on 18 September 2020. It was last reviewed this date.

This website was last tested on 6 June 2020 by Nomensa.

How we test this website

We test this website using automated and manual accessibility tests. Both types of testing are run against the W3C WAI Web Content Accessibility Guidelines version 2.1.

 

We do manual testing by selecting a representative sample of web pages (typically between 10 and 20 pages) and check that they are compliant with the guidelines. Our testers use the WAVE Chrome browser extension, which applies a range of checks to the web page under test. Our testers also manually navigate around the pages and check that content is presented in a logical order.

We use a Microsoft Tool, Accessibility Insights, to carry out automatic testing.